The GLOVe regimen, combining glofitamab, lenalidomide, and venetoclax, shows rapid and deep responses in high-risk MCL patients with manageable toxicity. All evaluable patients achieved complete ...
Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results